xmlns="http://www.w3.org/1999/xhtml"> home

JS Genetics

Develops and markets proprietary, low cost, high value DNA diagnostic testsfor underserved medical conditions in newborns, children, and adolescents. This focus grew out of the recognition that most genetic tests require blood samples, have longer turn-around times, and are expensive. The Company's principle strategy is to internally develop tests using cheek swabs for sample collection and a PCR based testing platform to bring to market accurate, convenient and cost effective DNA screening tests for adolescents focused in three key areas of developmental disorders:

Physical Development:
Turner Syndrome
Klinefelter Syndrome
Down's Syndrome

Cognitive Development:
Klinefelter Syndrome  

Behavioral Development:
Fragile X
Klinefelter Syndrome  

X Chromosome Abnormality Test (XCAT)

PCR and quantitative pyrosequencing based technology uses a simple cheek swab to accurately determine chromosomal abnormalities. Each kit contains two buccal swabs to collect the DNA and various tests can be performed for each patient sample collected. Kits are sent to healthcare Practitioners free of charge, and patient's insurance will be billed for services rendered.

XCAT-TS: Is a novel molecular genetic test for detection of Classic and Mosaic Turner Syndrome.  This test is now available to licensed Healthcare Practitioners- to order kits click here.

XCAT-KS: Is a genetic test for Klinefelter Syndrome, one of the most common genetic abnormalities in males.  This test is now available to licensed Healthcare Practitioners. Read more...

XCAT-FX: Is a test for Fragile X Syndrome, the most common know single gene genetic cause of autism, the most common hereditary cause of mental impairment in men and a major cause of infertility among women. This test is now available to licensed Healthcare Practitioners. Read more...

XCAT-DS: Is a test for Down’s Syndrome/Trisomy 18. Early stage development work is underway for this product. Read more...

XCAT-DX: Is a cheek swab test for pre-disposition to Dyslexia, a learning disability that can hinder a person's ability to read, write, spell and sometimes speak. Dyslexia is the most common learning disability in children - and it persist throughout life. The severity of Dyslexia can vary from mild to severe. Pre-clinical development work is underway for this product.

All of the analytical work is performed in our CLIA certified and CAP Accredited laboratory
CLIA ID# 07D1091103 CAP accredited CAP# 721-5351


JS Genetics Chooses XIFIN for Revenue Cycle Management and Commercialization Strategies.More...
JS Genetics receives CAP accreditation from College of American Pathology. More...
JS Genetics presents to Yale & CURE BioHaven Entrepreneurship Series. More...
NICHD approves JS Genetics funding for a NIH Phase 2 Development of Novel Diagnostic More...
Results of XCAT-TS validation Study are published in the Journal of Clinical Endocrinology & Metabolism…More
JS Genetics Develops New Non-Invasive Test, XCAT-TS, to Help Doctors Diagnose Turner Syndrome More...